Free Trial

Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
Dividend Yield
Price Target
KDNY stock logo

About Chinook Therapeutics Stock (NASDAQ:KDNY)

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

KDNY Stock News Headlines

URGENT: Prepare for Biden’s Digital Dollar NOW
Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.
Chinook Elementary
Chinook Therapeutics, Inc. (KDNY)
Expert Ratings for Chinook Therapeutics
URGENT: Prepare for Biden’s Digital Dollar NOW
Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.
Chinook Therapeutics (NASDAQ: KDNY)
Why Are Chinook Therapeutics Shares Trading Higher Today
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Novartis Buys Chinook: M&A To Drive Future Growth
Chinook Shareholder Action Reminder
Chinook Shareholder Notice
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share


Free Float
Market Cap
$2.90 billion
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

KDNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings
or view top-rated stocks.

What is Chinook Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Chinook Therapeutics' shares. Their KDNY share price targets range from $40.00 to $42.00. On average, they expect the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 1.5% from the stock's current price.
View analysts price targets for KDNY
or view top-rated stocks among Wall Street analysts.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.03. The firm had revenue of $1.83 million for the quarter, compared to analysts' expectations of $0.14 million. Chinook Therapeutics had a negative net margin of 4,199.93% and a negative trailing twelve-month return on equity of 58.28%. Chinook Therapeutics's revenue for the quarter was down 32.2% on a year-over-year basis.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

This page (NASDAQ:KDNY) was last updated on 6/25/2024 by Staff

From Our Partners